FDMT
NASDAQ · Biotechnology
4D Molecular Therapeutics In
$8.61
-0.37 (-4.12%)
Financial Highlights (FY 2026)
Revenue
36.5K
Net Income
-155,328,961
Gross Margin
—
Profit Margin
-434,778.4%
Rev Growth
-87.3%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 28.7% | 28.7% |
| Operating Margin | -507,678.4% | -456,911.7% | -31.5% | -30.2% |
| Profit Margin | -434,778.4% | -413,039.5% | -25.3% | -27.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 36.5K | 286.9K | 228.58M | 262.66M |
| Gross Profit | — | — | 65.62M | 75.40M |
| Operating Income | -185,099,537 | -1,310,696,957 | -72,020,646 | -79,353,945 |
| Net Income | -155,328,961 | -1,099,890,361 | -57,732,834 | -71,516,444 |
| Gross Margin | — | — | 28.7% | 28.7% |
| Operating Margin | -507,678.4% | -456,911.7% | -31.5% | -30.2% |
| Profit Margin | -434,778.4% | -413,039.5% | -25.3% | -27.2% |
| Rev Growth | -87.3% | -87.3% | +10.3% | +10.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 29.62M | 33.00M |
| Total Equity | — | — | 238.80M | 269.31M |
| D/E Ratio | — | — | 0.12 | 0.12 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -176,955,528 | -1,322,641,633 | -107,016,126 | -112,376,502 |
| Free Cash Flow | — | — | -89,291,698 | -82,297,413 |